公开(公告)号：US11591590B2

公开(公告)日：2023-02-28

申请号：US16850727

申请日：2020-04-16

Applicant: General Electric Company

Inventor： Vasile Bogdan Neculaes ,  Andrew Soliz Torres ,  Steve Lambert Klopman

IPC: C12N13/00 ,  C12N5/078 ,  A61K35/19 ,  A61K38/18 ,  A61K33/06 ,  A61K41/00

Abstract: The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.

公开(公告)号：US20200239868A1

公开(公告)日：2020-07-30

申请号：US16850727

申请日：2020-04-16

Applicant: General Electric Company

Inventor： Vasile Bogdan Neculaes ,  Andrew Soliz Torres ,  Steve Lambert Klopman

IPC: C12N13/00 ,  C12N5/078 ,  A61K35/19 ,  A61K38/18 ,  A61K41/00

Abstract: The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.

公开(公告)号：US20170191052A1

公开(公告)日：2017-07-06

申请号：US14984988

申请日：2015-12-30

Applicant: GENERAL ELECTRIC COMPANY

Inventor： Vasile Bogdan Neculaes ,  Andrew Soliz Torres ,  Steve Lambert Klopman

IPC: C12N13/00 ,  C12N5/078

CPC classification number: C12N13/00 ,  A61K33/06 ,  A61K35/19 ,  A61K38/18 ,  A61K41/00 ,  C12N5/0644 ,  A61K2300/00

Abstract: The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.